cannabidiol Indications/Contra | FAERs-F | FAERs-M | Orange Bk | BioActivity |

Stem definitionDrug idCAS RN
5288 13956-29-1

Description:

MoleculeDescription

Molfile Inchi Smiles

Synonyms:

  • cannabidiol
  • GWP42003-P
  • epidiolex
The precise mechanisms by which cannabidiol exerts its anticonvulsant effect in humans are unknown. Cannabidiol does not appear to exert its anticonvulsant effects through interaction with cannabinoid receptors.
  • Molecular weight: 314.47
  • Formula: C21H30O2
  • CLOGP:
  • LIPINSKI: None
  • HAC: 2
  • HDO: 2
  • TPSA: 40.46
  • ALOGS:
  • ROTB: 6

Drug dosage:

None

ADMET properties:

PropertyValueReference
Vd (Volume of distribution) 6.69 L/kg Lombardo F, Berellini G, Obach RS
CL (Clearance) 13.55 mL/min/kg Lombardo F, Berellini G, Obach RS
t_half (Half-life) 23.82 hours Lombardo F, Berellini G, Obach RS

Approvals:

DateAgencyCompanyOrphan
Sept. 19, 2019 EMA GW Pharma (International) B.V.
June 25, 2018 FDA GW RESEARCH LTD

FDA Adverse Event Reporting System (Female)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Device related thrombosis 105.43 23.20 23 3289 1204 46681546
Nail disorder 59.38 23.20 22 3290 7874 46674876
Large intestine polyp 55.82 23.20 21 3291 7840 46674910
Multiple-drug resistance 51.40 23.20 15 3297 2550 46680200
Blood pressure diastolic decreased 46.90 23.20 22 3290 14189 46668561
Drug resistance 45.62 23.20 23 3289 17345 46665405
Body temperature decreased 45.00 23.20 21 3291 13388 46669362
Heart rate irregular 41.30 23.20 22 3290 18569 46664181
Urine leukocyte esterase positive 38.61 23.20 12 3300 2523 46680227
Tonic convulsion 38.57 23.20 10 3302 1096 46681654
Skin exfoliation 36.67 23.20 25 3287 32913 46649837
Therapeutic product effective for unapproved indication 35.94 23.20 6 3306 72 46682678
Blood pressure systolic increased 34.80 23.20 23 3289 28764 46653986
Diarrhoea 33.59 23.20 101 3211 559501 46123249
Drug interaction 33.33 23.20 55 3257 203039 46479711
Urine abnormality 32.78 23.20 13 3299 5581 46677169
Hip fracture 31.57 23.20 21 3291 26535 46656215
Infusion site scar 30.07 23.20 6 3306 202 46682548
Therapeutic product ineffective for unapproved indication 30.07 23.20 6 3306 202 46682548
Breast cancer metastatic 29.85 23.20 16 3296 13662 46669088
Metastases to liver 29.54 23.20 18 3294 19567 46663183
Tri-iodothyronine free decreased 29.34 23.20 6 3306 229 46682521
Metastases to bone 28.79 23.20 17 3295 17459 46665291
Drug level increased 27.94 23.20 17 3295 18424 46664326
Creatinine urine decreased 25.24 23.20 5 3307 162 46682588
Productive cough 25.21 23.20 24 3288 50691 46632059
Wheezing 24.16 23.20 24 3288 53362 46629388

FDA Adverse Event Reporting System (Male)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Drug interaction 64.89 32.30 63 1411 199505 29751499
Seizure 58.44 32.30 44 1430 98431 29852573
Social avoidant behaviour 37.12 32.30 11 1463 2852 29948152
Behaviour disorder 34.49 32.30 10 1464 2402 29948602
Alcohol intolerance 33.49 32.30 7 1467 433 29950571

Pharmacologic Action:

SourceCodeDescription
ATC N03AX24 NERVOUS SYSTEM
ANTIEPILEPTICS
ANTIEPILEPTICS
Other antiepileptics
FDA CS M0003267 Cannabinoids
MeSH PA D000927 Anticonvulsants
MeSH PA D002491 Central Nervous System Agents
FDA MoA N0000182138 Cytochrome P450 1A2 Inhibitors
FDA MoA N0000182139 Cytochrome P450 2B6 Inhibitors
FDA MoA N0000182140 Cytochrome P450 2C19 Inhibitors
FDA MoA N0000185504 Cytochrome P450 2C9 Inhibitors
FDA MoA N0000187062 Cytochrome P450 2C8 Inhibitors
FDA MoA N0000187064 Cytochrome P450 2B6 Inducers
FDA MoA N0000191273 UGT2B7 Inhibitors
FDA MoA N0000191278 UGT1A9 Inhibitors
CHEBI has role CHEBI:76924 plant metabolites

Drug Use (View source of the data)

DiseaseRelationSNOMED_IDDOID
Lennox-Gastaut syndrome indication 230418006
Severe myoclonic epilepsy in infancy indication 230437002

Acid dissociation constants calculated using MoKa v3.0.0

Dissociation levelDissociation constantType (acidic/basic)
pKa1 9.34 acidic
pKa2 11.34 acidic

Orange Book patent data (new drug applications)

None

Orange Book exclusivity data (new drug applications)

Formulation strengthTrade nameApplicantApplication numberApproval dateTypeDose formRouteExclusivity dateDescription
100MG/ML EPIDIOLEX GW RES LTD N210365 Sept. 28, 2018 RX SOLUTION ORAL July 31, 2023 NEW PATIENT POPULATION
100MG/ML EPIDIOLEX GW RES LTD N210365 Sept. 28, 2018 RX SOLUTION ORAL Sept. 28, 2023 NEW CHEMICAL ENTITY
100MG/ML EPIDIOLEX GW RES LTD N210365 Sept. 28, 2018 RX SOLUTION ORAL Sept. 28, 2025 INDICATED FOR THE TREATMENT OF SEIZURES ASSOCIATED WITH LENNOX-GASTAUT SYNDROME (LGS) OR DRAVET SYNDROME (DS) IN PATIENTS 2 YEARS OF AGE AND OLDER
100MG/ML EPIDIOLEX GW RES LTD N210365 Sept. 28, 2018 RX SOLUTION ORAL July 31, 2027 TREATMENT OF SEIZURES ASSOCIATED WITH LENNOX-GASTAUT SYNDROME (LGS) OR DRAVET SYNDROME (DS) IN PATIENTS BETWEEN 1 AND 2 YEARS OF AGE
100MG/ML EPIDIOLEX GW RES LTD N210365 Sept. 28, 2018 RX SOLUTION ORAL July 31, 2027 TREATMENT OF SEIZURES ASSOCIATED WITH TUBEROUS SCLEROSIS COMPLEX (TSC) IN PATIENTS 1 YEAR OF AGE AND OLDER

Bioactivity Summary:

TargetClassPharosUniProtActionTypeActivity value
(-log[M])
Mechanism
action
Bioact sourceMoA source
G-protein coupled receptor 55 GPCR ANTAGONIST UNKNOWN SCIENTIFIC LITERATURE
Transient receptor potential cation channel subfamily V member 1 Ion channel INHIBITOR UNKNOWN SCIENTIFIC LITERATURE

External reference:

IDSource
4036658 VANDF
C0006863 UMLSCUI
CHEBI:69478 CHEBI
P0T PDB_CHEM_ID
CHEMBL190461 ChEMBL_ID
DB09061 DRUGBANK_ID
D002185 MESH_DESCRIPTOR_UI
D10915 KEGG_DRUG
10423 INN_ID
644019 PUBCHEM_CID
4150 IUPHAR_LIGAND_ID
C000628684 MESH_SUPPLEMENTAL_RECORD_UI
19GBJ60SN5 UNII
2045371 RXNORM
20468 MMSL
291103 MMSL
d08919 MMSL
010751 NDDF
771981005 SNOMEDCT_US
96223000 SNOMEDCT_US

Pharmaceutical products:

ProductCategoryIngredientsNDCFormQuantityRouteMarketingLabel
Epidiolex HUMAN PRESCRIPTION DRUG LABEL 1 70127-100 SOLUTION 100 mg ORAL NDA 31 sections
NanoCDB HUMAN OTC DRUG LABEL 1 70658-122 SOLUTION/ DROPS 1.94 g BUCCAL Export only 8 sections
leafPro CBDmed Oil FS QP 3% HUMAN OTC DRUG LABEL 1 73674-001 OIL 3 g ORAL unapproved drug other 15 sections
leafPro CBDmed Oil FS QP 5% HUMAN OTC DRUG LABEL 1 73674-002 OIL 5 g ORAL unapproved drug other 15 sections
leafPro CBDmed Oil FS QP 20% HUMAN OTC DRUG LABEL 1 73674-005 OIL 20 g ORAL unapproved drug other 15 sections
leafPro CBDmed Oil T-FS QD 3% HUMAN OTC DRUG LABEL 1 73674-020 OIL 3 g ORAL unapproved drug other 15 sections
leafPro CBDmed Oil T-FS QD 5% HUMAN OTC DRUG LABEL 1 73674-021 OIL 5 g ORAL unapproved drug other 15 sections
leafPro CBDmed Oil T-FS QD 20% HUMAN OTC DRUG LABEL 1 73674-024 OIL 20 g ORAL unapproved drug other 15 sections
leafPro CBDmed Softgels FS QP 20 HUMAN OTC DRUG LABEL 1 73674-052 CAPSULE, LIQUID FILLED 20 mg ORAL unapproved drug other 15 sections
leafPro CBDmed Softgels T-FS QD 20 HUMAN OTC DRUG LABEL 1 73674-061 CAPSULE, LIQUID FILLED 20 mg ORAL unapproved drug other 15 sections
Kaydia Patch HUMAN OTC DRUG LABEL 3 75140-002 PATCH 0.15 g TOPICAL unapproved drug other 8 sections